FDA Grants Fast Track Designation to Posdinemab for Early Alzheimer's Disease

Retrieved on: 2025-01-08 19:05:52

Tags for this article:

Click the tags to see associated articles and topics

FDA Grants Fast Track Designation to Posdinemab for Early Alzheimer's Disease. View article details on hiswai:

Excerpt

The US FDA has granted Fast Track designations to Johnson & Johnson's posdinemab, a phosphorylated tau–directed monoclonal antibody (mAb) ...

Article found on: www.patientcareonline.com